PROTAC CDK9 degrader-5

Cat. No.:	HY-149962
CAS No.:	2935587-89-4
Molecular Formula:	$C_{42}H_{48}Cl_2N_8O_9$
Molecular Weight:	879.78
Target:	CDK; PROTACs
Pathway:	Cell Cycle/DNA Damage; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC CDK9 degrader-5 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-5 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-5 degrades CDK9 with DC_{50}s of 0.10 μM and 0.14 μM for the $CDK9_{42}$ and $CDK9_{55}$ isoforms, respectively[1].	
IC_{50} & Target	$CDK9_{42}$ 0.10 μM (DC50)	$CDK9_{55}$ 0.14 μM (DC50)

In Vitro

PROTAC CDK9 degrader-5 (compound 15e) (1 μM; 6 h) decreases the protein level of MCL2, and competely degrades CDK9 in MV411 cells[1].

PROTAC CDK9 degrader-5 (1 μM; 1-6 h) time-dependently decreases the protein level of MCL2, and CDK9, and remaines suppression for 24 h[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MV411 cells
Concentration:	1 μM
Incubation Time:	1 h, 2 h, 4 h, 6 h
Result:	Degraded CDK9 starting at 2 h incubation and reaching a plateau at 4 h. Remained suppressed for 24 h with some recurrence at 48 h after finished treatment.

REFERENCES

[1]. Tokarski RJ 2nd, et al. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. Eur J Med Chem. 2023 Jun 5;254:115342.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA